BeiGene, Ltd. Total Liabilities
BeiGene, Ltd. total liabilities. Based on the latest financial reports, BeiGene, Ltd. (ONC) has total liabilities worth $3.79 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BeiGene, Ltd. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BeiGene, Ltd. (2013–2025)
Total liabilities of BeiGene, Ltd. from 2013 to 2025. This chart illustrates how BeiGene, Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of BeiGene, Ltd. to see how much of total assets are deployed in long-term investments.
BeiGene, Ltd. Competitors by Total Liabilities
The table below lists competitors of BeiGene, Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Svenska Handelsbanken AB (publ)
ST:SHB-A
|
Sweden | Skr3.69 Trillion |
|
Banco Bradesco DRC
BA:BBD
|
Argentina | AR$2.03 Trillion |
|
SANDVIK AB SP.ADR
F:SVK
|
Germany | €81.89 Billion |
|
Martin Marietta Materials Inc
NYSE:MLM
|
USA | $9.76 Billion |
|
ABN Amro Group NV
AS:ABN
|
Netherlands | €445.70 Billion |
|
EQT Corporation
NYSE:EQT
|
USA | $12.46 Billion |
|
Muyuan Foodstuff Co Ltd
SHE:002714
|
China | CN¥89.89 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $13.24 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down BeiGene, Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BeiGene, Ltd. (ONC) total assets.
Liquidity & Leverage Metrics
BeiGene, Ltd. Total Liabilities Ratios Explained
BeiGene, Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BeiGene, Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BeiGene, Ltd. (2013–2025)
The table below shows the annual total liabilities of BeiGene, Ltd. from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.83 Billion | +47.85% |
| 2024-12-31 | $2.59 Billion | +14.14% |
| 2023-12-31 | $2.27 Billion | +13.63% |
| 2022-12-31 | $2.00 Billion | -16.94% |
| 2021-12-31 | $2.40 Billion | +38.78% |
| 2020-12-31 | $1.73 Billion | +173.14% |
| 2019-12-31 | $633.93 Million | +27.80% |
| 2018-12-31 | $496.04 Million | +36.93% |
| 2017-12-31 | $362.25 Million | +584.70% |
| 2016-12-31 | $52.91 Million | +24.65% |
| 2015-12-31 | $42.45 Million | +52.39% |
| 2014-12-31 | $27.85 Million | -42.87% |
| 2013-12-31 | $48.76 Million | -- |
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more